CS MEDICA Group Achieves Complete Registration of CANNASEN® CBD-Infused Medical Devices in Israel

CS MEDICA Group has announced the successful registration of its entire CANNASEN® portfolio of CBD-infused medical devices in Israel. This accomplishment marks the first complete product portfolio of over-the-counter products containing CBD approved by Israel's Ministry of Health. The registration was completed through collaboration with Forbe Healthcare Ltd.

In August 2022, CS MEDICA's subsidiary CANNORDIC entered a distribution agreement with Forbe Healthcare Ltd. The agreement covers the distribution of 852,000 units valued at DKK 37.1 million over the next 3.5 years. The CANNASEN® Pain Patch, the first product launched, faced delays but was successfully introduced in December 2024.

Despite regulatory changes and regional conflicts, the entire product registration was eventually completed. The US FDA approval played a crucial role in facilitating the process. CEO Lone Henriksen emphasized the resilience and strategic focus required to navigate the regulatory environment and market conditions.

As preparations for production and market launch continue, CANNORDIC and Forbe Healthcare are committed to adapting their strategies to reflect current market conditions. The aim is to provide high-quality healthcare solutions responsibly.